missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human SPPL2A (aa 31-99) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (72%), Rat (72%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-57509 (PA5-57509. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
By searching sequence databases for homologs of Dictyostelium discoideum Impas, which shares homology with presenilin, followed by PCR of lymphocyte and hippocampus cDNA libraries, Grigorenko et al. (2002) cloned SPPL2a. This protein, which may act as an intramembrane protease, contains an N-terminal protease-associated (PA) domain, several transmembrane regions, a hydrophilic loop, conservative sequences around the first and second aspartate residues, and an invariant PAL motif near the C terminus.
Specifications
Specifications
| Accession Number | Q8TCT8 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 84888 |
| Name | Human SPPL2A (aa 31-99) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2010106G01Rik; C130089K23Rik; IMP3; IMP-3; intramembrane cleaving protease; intramembrane protease 3; MNCb-3763; Presenilin-like protein 2; protein SPPL2a; PSEC0147; PSL2; RGD1563001; signal peptide peptidase like 2 A; signal peptide peptidase-like 2 A; SPPL2A; SPPL2a protein; SPP-like 2 A; SPP-like 2 A protein |
| Common Name | SPPL2A |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction